Filing Flows › Tarsus Pharmaceuticals (TARS) › Stock forecast & fair value
Tarsus Pharmaceuticals (TARS) stock forecast and price target
Tarsus Pharmaceuticals (TARS) trades at $68.60. 9 analysts' median price target is $103.00 (+50%), from $88.00 to $116.00.
Tarsus Pharmaceuticals' latest quarter
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for TARS stock?
The median of 9 analysts' 12-month targets is $103.00, +50% from $68.60; the range is $88.00 to $116.00. The average rating is strong buy.
Does Tarsus Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is TARS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.